FOLH1 and prostate carcinoma: 18F-Fluciclovine, 68Ga-PSMA, and 18F-DCFPyL PET/CT are currently approved by the Food and Drug Administration (FDA) for men with suspected prostate cancer recurrence, but worldwide approval and funding awaits evidence of improved patient outcomes.